medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Association between angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers use and the risk of infection and clinical outcome of COVID-19: a comprehensive systematic review and meta-analysis.

Guangbo Qu, MD[1a], Liqin Shu, MD[2a], Evelyn J. Song, MD[3], Dhiran Verghese, MD[4], John Patrick Uy, MD[4], Ce Cheng, DO[5], Qin Zhou, PhD[6], Hongru Yang MD[7], Zhichun Guo MD[7], Mengshi, Chen[8], Chenyu Sun, MD, MSc[4,*]

1. Department of Epidemiology and Health Statistics, School of Public Health, Anhui Medical University, No. 81 Meishan Road, Hefei 230032, Anhui, China.

2. Department of Child Health care, Maternal and Child Health Care Hospital of Anhui Province (Affiliated Maternal and Child Health Care Hospital of Anhui Medical University), Hefei 230001, Anhui, China.

3. Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.

4. AMITA Health Saint Joseph Hospital Chicago, 2900 N. Lake Shore Drive, Chicago, 60657, Illinois, USA

5. Department of Internal Medicine, Cape Fear Valley Medical Center, Fayetteville 28304, NC, USA

6. Mayo Clinic, Rochester, MN 55905, USA

7. Massachusetts College of Pharmacy and Health Science, 179 Longwood Ave, Boston, 02115, MA, USA

8. Hunan Provincial Key Laboratory of Clinical Epidemiology, Xiangya School of Public Health, Central South University.

a. Guangbo Qu and Liqin Shu contributed equally to this study and should be considered as co-joint first authors.

*Correspondence to: Chenyu Sun, Internal Medicine, AMITA Health Saint Joseph Hospital Chicago, Lake Shore Drive Chicago, Illinois 60657, Chicago, USA. E-mail: drsunchenyu@yeah.net.

Short title: ACEIs and ARBs use and COVID-19 risk

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Abstract

Background The effect of using Angiotensin-converting enzyme inhibitors (ACEIs) and Angiotensin-receptor blockers (ARBs) on the risk of coronavirus disease 2019 (COVID-19) is a topic of recent debate. Although studies have examined the potential association between them, the results remain controversial. This study aims to determine the true effect of ACEI/ARBs use on the risk of infection and clinical outcome of COVID-19.

Methods Five electronic databases (PubMed, Web of science, Cochrane library, China National Knowledge Infrastructure database, medRxiv preprint server) were retrieved to find eligible studies. Meta-analysis was performed to examine the association between ACEI/ARBs use and the risk of infection and clinical outcome of COVID-19.

Results 22 articles containing 157,328 patients were included. Use of ACEI/ARBs was not associated with increased risk of infection (Adjusted OR: 0.96, 95% CI: 0.91-1.01, I^2=5.8%) or increased severity (Adjusted OR: 0.90, 95% CI: 0.77-1.05, I^2=27.6%) of COVID-19. The use of ACEI/ARBs was associated with lower risk of death from COVID-19 (Adjusted OR: 0.66, 95% CI: 0.44-0.99, I^2=57.9%). Similar results of reduced risk of death were also found for ACEI/ARB use in COVID-19 patients with hypertension (Adjusted OR: 0.36, 95% CI: 0.17-0.77, I^2=0).

Conclusion This study provides evidence that ACEI/ARBs use for COVID-19 patients does not lead to harmful outcomes and may even provide a beneficial role and decrease mortality from COVID-19. Clinicians should not discontinue ACEI/ARBs for patients diagnosed with COVID-19 if they are already on these agents.

medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Keywords: COVID-19; Angiotensin-converting enzyme inhibitor; Angiotensin-receptor blockers; risk; systematic review; meta-analysis.

1. Introduction

In December 2019, the first case of novel coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in Wuhan, China [1, 2]. Due to the rapidly increasing number of cases worldwide, on March 11, 2020, the World Health Organization (WHO) declared the COVID-19 outbreak a global pandemic As of June 3, 2020, there were 6, 287, 771 confirmed cases and 379, 941 deaths globally per WHO [3]. COVID-19 has greatly impacted both professional and personal lives of everyone worldwide.

The epidemiological and clinical characteristics of COVID-19 have been well described in previous studies [4, 5]. Hypertension, diabetes and cardiovascular diseases (CVD) including congestive heart failure (CHF) and myocardial infarction are common comorbidities reported in patients with COVID-19 and have been associated with a poor prognosis [5, 6]. Angiotensin-converting enzyme inhibitors (ACEIs) and Angiotensin-receptor blockers (ARBs) are first line anti-hypertensive medications and are included in the guideline-directed therapy for diabetic nephropathy, CHF and myocardial infarction. Angiotensin-converting enzyme 2 (ACE2), a membrane-bound aminopeptidase, is widely expressed in certain tissues of human body including lung, intestine, heart, and

medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

kidneys, and it has been shown that the use of ACEIs and ARBs can increase the expression of ACE2 [7, 8]. Furthermore, ACE2 acts as a functional receptor and SARS-CoV-2 utilizes the ACE2 for attachment of its spike protein, in the process of its entrance into cells [9,10]. These findings led some investigators to hypothesize that the use of ACEIs or ARBs may increase the risk of infection by SARS-CoV-2 and the severity of COVID-19 [11-13].

Several clinical studies have been conducted to test this hypothesis. However, a consensus has not been reached regarding how the use of ACEIs or ARBs affects the outcome of patients with COVID-19. The goal of this meta-analysis is to clarify the effects of ACEIs and/or ARBs on the infection risk, severity, and mortality of COVID-19, hoping to shed more light in the prevention and treatment of the current ongoing pandemic.

2. Methods

This study was conducted and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [14].

2.1 Literature search and data source

We searched five electronic databases (PubMed, Web of science, Cochrane library, China National Knowledge Infrastructure database, medRxiv preprint server) to collect relevant studies published until May 20, 2020. The search strategy was established and performed by two authors. The search terms used included the following: (angiotensin-converting-enzyme inhibitor OR ACEI OR angiotensin-receptor blockers OR

medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

ARB) AND (coronavirus OR COVID-19 OR SARS-CoV-2). There was no language limitation on the search. All references of included studies were evaluated for additional studies to include as many eligible studies as possible. For retrieved records, we used reference management software (NoteExpress, college version) to save and filter.

2.2 Study selection

First, we reviewed the title and abstract of retrieved studies and excluded irrelevant ones. Then, we read through the full-text of remaining studies and included eligible studies based on our inclusion and exclusion criteria. Our inclusion criteria are as follows: (1) participants were patients diagnosed with COVID-19; (2) patients were reported as having ACEI and/or ARB exposure and non-ACEI and/or ARB exposure (ACEI use versus non-ACEI use; ARB use versus non-ARB use; ACEI/ARB use versus non-ACEIARB use); (3) at least one of following outcomes of COVID-19 was reported: positive rate/infection rate, hospital admission rate, severity, mortality in groups of ACEI and/or ARB exposure and non-ACEI and/or ARB exposure or the association between ACEI and/or ARB exposure and the risk of infection, hospital admission, severity, and death due to COVID-19; (4) the study design was case-control or cohort. Exclusion criteria are as follows: (1) the studies were reviews, case-reports, or animal experiments; (2) studies did not meet the inclusion criteria; (4) The data of interest was not reported; (4) no clear definition or diagnose methods of COVID-19. Two authors (Guangbo Qu and Liqin Shu) conducted the selections independently, and any disagreement was solved through discussion.

medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

2.3 Data extraction and quality assessment

Following information was extracted using a standard chart form: first author's name, number of patients, number of patients in ACEI/ARB exposure (only ACEI exposure, only ARB exposure, either ACEI or ARB exposure) and non-exposure groups, patients' characteristics, infection risk, hospital admission, severity, and mortality of patients in each group, odds ratios (ORs) or risk ratios (RRs) or hazard ratio (HRs) of the infection, hospital admission, severity, and mortality of COVID-19.

Considering that the included studies were observational studies, the Newcastle-Ottawa Scale (NOS) was used to assess the quality from three aspects: (1) selection of participants; (2) comparability of groups; (3) assessment of exposure and outcome [15]. NOS contained eight items with scores ranging from 0 to 9 stars. The quality of studies was divided into three categories based on the scores: low quality is 0-3 stars, moderate quality is 4-5 stars, and high quality is 6 stars or above. Two authors (Guangbo Qu and Liqin Shu) assessed quality independently, and disagreement was resolved by consensus.

3. Statistical analysis

Meta-analyses were conducted to assess for associations. Crude and adjusted odds ratios (Crude OR and Adjusted OR), with corresponding 95% confidence intervals, were calculated using the extracted binary data or effect sizes that was reported in all studies. Additionally, if available, Crude OR and/or Adjusted OR were also calculated to explore the association

medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

between ACEI/ARB use and outcomes of COVID-19 among patients with hypertension. The statistical heterogeneity between studies was identified using the Cochrane's Q test and I-square test. Heterogeneity was present if P value of Q test was less than 0.1 or the value of I^2 was more than 50% [16]. The model for meta-analyses was chosen based on the level of heterogeneity between studies; if obvious heterogeneity was present, then random-effects model was used, otherwise, the fix-effects model was used [17]. Subgroup analysis was conducted based on the characteristics of included studies. Publication bias was identified via Begg's and Egger's tests. If P value of Begg's and Egger's tests were more than 0.05, then publication bias is present. Sensitivity analysis was performed by omitting studies one by one to assess the stability of pooled results. All statistical analyses were performed using STATA software (version 14.0) and Review Manager (version 5.3).

4. **Results**

4.1 Characteristics of included studies

After initial search, 477 records were retrieved (PubMed: n=166, Web of science: n=228, Cochrane library: n=9, China National Knowledge Infrastructure database: n=27, medRxiv preprint server: n=41, Other sources: n=6). 27 records were excluded for duplication. After reading the titles and abstracts, 391 records were excluded due to irrelevance. After study selection according to the inclusion and exclusion criteria, 36 articles were excluded and one study was further excluded because it was retracted by the journal. Finally, 22 articles containing 157,328 patients were included in this meta-analysis [8, 10, 18-37]. The flow chart

medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

of the selection process is displayed in Figure 1.

The characteristics of included studies were shown in Table 1. Of included studies, 11 were conducted in China [8,16,20,21,22,24,25,27,33,35,36], seven were from the United States [19,23,28,29,32,34,37], two were from Italy [10,30], one from Spain [26]. All, but three, were cohort studies. The sample size of each study ranged from 42 to 37,031. Multiple comorbidities were reported and all patients in eight of the studies had hypertension [8,18,22,25,27,32,33,37]. Majority of the studies were high quality studies. Detailed quality assessment results are in Table S1.

4.2 ACEI/ARB use and COVID-19 infection

Pooled meta-analyses showed that, without adjusting for any confounders, ACEI, ARB, and ACEI/ARB use were not significantly associated with the risk of COVID-19 infection (Crude OR: 1.27, 95% CI: 0.95-1.69 for ACEI use; Crude OR: 1.07, 95% CI: 0.76-1.50 for ABR use; Crude OR: 1.10, 95% CI: 0.84-1.43 for ACEI/ARB use); however, obvious heterogeneity was present between studies (All I^2 >50%) (Table 2, Figure 2). Similarly, after adjusting for confounders, ACEI, ARB, and ACEI/ARB use were not significantly associated with the risk of COVID-19 infection (Adjusted OR: 0.94, 95% CI: 0.87-1.01, I^2=0 for ACEI use; Adjusted OR: 0.73, 95% CI: 0.49-1.09, I^2=95.1% for ABR use; Adjusted OR: 0.96, 95% CI: 0.91-1.01, I^2=5.8% for ACEI/ARB use). Furthermore, subgroup analysis based on different characteristics of studies showed no correlation between the use of ACEI and/or ARB and risk of COVID-19 infection.

medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

4.3 ACEI/ARB use and hospital admission for COVID-19

Pooled meta-analyses showed that patients using ACEI, ARB, and ACEI/ARB had higher risk of hospital admission for COVID-19 compared to patients not using these medications (Adjusted OR: 1.29, 95% CI: 1.07-1.57, I^2=62.4% for ACEI use; Adjusted OR: 1.69, 95% CI: 1.46-1.96, I^2=0 for ABR use; Adjusted OR: 1.38, 95% CI: 1.21-1.57, I^2=34.5% for ACEI/ARB use) (Table 2 and Figure 3).

4.4 ACEI/ARB use and severity of COVID-19

Use of ACEI, ARB, and ACEI/ARB was not associated with severity of COVID-19 infection for both pooled crude and adjusted OR (Adjusted OR: 0.90, 95% CI: 0.72-1.14, I^2=0 for ACEI use; Adjusted OR: 0.91, 95% CI: 0.74-1.13, I^2=45.8% for ABR use; Adjusted OR: 0.90, 95% CI: 0.77-1.05, I^2=27.6% for ACEI/ARB use). Additionally, subgroup analysis based on different characteristics (study design, region, race, study quality) also did not show any significant association (Table 2 and Figure 4). Furthermore, for patients with hypertension, ACEI, ARB, and ACEI/ARB use was not significantly associated with severity of COVID-19 infection (Table S2).

4.5 ACEI/ARB use and COVID-19 related mortality

Only one study reported the association between ACEI and ARB use and risk of death from COVID-19 without adjusting confounders separately (OR: 0.91, 95% CI: 0.38-2.17 for

medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

ACEI use; OR: 0.77, 95% CI: 0.41-1.43 for ABR use) [18]. Only one study reported no significant association between ACEI use and risk of death from COVID-19 (OR: 0.97, 95% CI: 0.69-1.34) [30]. The pooled crude OR showed no significant association between ACEI/ARB use and risk of death from COVID-19 (Crude OR: 0.88, 95% CI: 0.66-1.18, I^2=60.9%). However, the pooled adjusted ORs showed that patients on ACEI/ARB had a lower risk of death from COVID-19 (Adjusted OR: 0.66, 95% CI: 0.44-0.99, I^2=57.9%). No study reported the association between ARB use and the risk of death from COVID-19 (Table 2 and Figure 5). Furthermore, subgroup analysis on studies from China or studies of Asian population found that ACEI/ARB use was associated with a lower risk of death from COVID-19. For patients with hypertension, ACEI/ARB use also was associated with a lower risk of death from COVID-19 (Adjusted OR: 0.36, 95% CI: 0.17-0.77, I^2=0) (Table S3).

4.6 Publication bias and results of sensitivity analysis

There was no significant publication bias among meta-analyses with two or more studies included (All P values were more than 0.05) based on Begg's and Egger's tests (Table S4). Sensitivity analysis showed that no study had significant impact on the stability of pooled results from meta-analyses.

5. Discussion

The effect of ACEI/ARB use on COVID-19 patients has been a controversial topic since the beginning of this pandemic. Based on prior studies on the effect of ACEI/ARBs on ACE2

medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

expression [7, 38, 39], it was initially hypothesized that increased expression of ACE2 from ACEI/ARB may increase the risk of SARS-COV-2 entrance into respiratory epithelial cells through binding to the structural transmembrane ACE2 receptor. Therefore, ACEI/ARB may theoretically increase the susceptibility of infection and lead to worse outcomes from COVID-19 [11, 40]. However, even though elevated expression of ACE2 caused by ACEI/ARB use has been found in animal studies [7, 38, 39], no evidence has indicated similar effects in human studies. Many studies have been published in the recent months attempting to better understand the effects of ACEI/ARB in COVID-19 patients [8, 10, 19, 29, 30].

Our systematic review and meta-analysis shows that ACEI/ARBs use is not significantly associated with increased infection risk and severity of COVID-19 and is actually associated with a decreased risk of death from COVID-19. However, it does lead to an increased risk of hospital admissions. The increased risk of hospitalization admissions in patients on ACEI/ARB should be interpreted with caution because in the included studies, residual confounding factors such as comorbidities like CVD were not well adjusted for [19, 30]. Patients who are taking ACEI/ARB likely have underlying cardiovascular comorbidities and prior studies demonstrated that patient comorbidities including hypertension and CVD are associated with severe COVID-19 infections, requiring hospitalization, and increased mortality [41, 42]. Therefore, additional large, prospective, randomized studies are needed to better characterize the effect of ACEI/ARB use on rate of hospitalization of COVID-19 patients.

medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Interestingly, the pooled crude ORs did not show significant association between ACEI/ARB use and the risk of death from COVID-19, but after pooling the adjusted ORs, ACEI/ARB use was associated with a decreased risk of death from COVID-19 in all patients and in those with hypertension. However, the crude OR did not found a significant association of ACEI use and the risk of death from COVID-19. This difference seen bet the crude and adjusted ORs is likely because some important confounders were adjusted for adjusted ORs, which may reflect the true association between ACEI/ARB use and risk of death from COVID-19. Additionally, none of the studies reported the association between ARB use and risk of death from COVID-19; therefore, pooled adjusted OR for ARBs was not calculated.

ACEI/ARBs are commonly used in the treatment of hypertension and CHF to inhibit Angiotensin II and downregulate the Renin-angiotensin-aldosterone system (RAAS) [43]. The decreased risk of death is likely due to continued management of patients' existing underlying diseases as poorly controlled hypertension and CHF are both associated with worse outcomes in COVID-19 patients [44]. Additionally, the anti-inflammatory and immune-modulatory properties of ACEI/ARBs may also explain their protective effect. Heightened inflammatory response is an important factor leading to adverse outcomes of COVID-19 patients [45]. Previously, it has been shown that Angiotensin II increases expression of inflammatory cytokines via activation of Angiotensin II receptor type 1 (AT1R) [46]. ACEI/ARB decreases the level of Angiotensin II, potentially attenuating the inflammatory response. Additionally, ACEI/ARB reduces T-cell depletion in peripheral blood

medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

and inhibits dendritic cell maturation and Th1 and Th17 cell polarization, resulting in a more potent immune system [47]. This hypothesis is supported in the study by Meng et al, in which it was demonstrated that ACEI/ARB use in COVID-19 patients was associated with lower IL-6 level, increased CD3 and CD8 T-cell counts, and decreased peak viral load [25].

This systemic review and meta-analysis comprehensively explored the effect of ACEI/ARB use on infection risk and different clinical outcomes related to COVID-19. Our study is consistent with results from prior studies on this topic, where they also demonstrated that ACEI/ARB use does not increase the severity of COVID-19 infection and decreases mortality [48-50]. Additionally, we also included information not available in previous systemic reviews such as the association between ACEI/ARB use and hospitalization due to COVID-19. This study helps to shed light into the current debate on the use of ACEI/ARBs in patients with COVID-19 and demonstrates that ACEI/ARB use does not lead to increased risk of COVID-19 infection and may even decrease the risk of death from COVID-19. The results from this study supports the joint statement from American Heart Association (AHA), Heart Failure Society of America (HFSA) and American College of Cardiology (ACC) and the statement from the European Society of Cardiology (ESC) Council on Hypertension that patients with COVID-19 taking ACEI/ARBs should continue their treatment [51].

A few limitations present in our study should be noted. First, all the studies included are observational studies, making it difficult to infer accurate causation. Second, no data was provided regarding the dose and exposure duration of ACEI/ARBs; therefore, we could not determinate whether COVID-19 infection is affected by the dose and duration of ACEI/ARBs

medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

exposure. Third, beta blockers can also prevent ACE2 activity [52], therefore, the effect of ACEI/ARB use may be underestimated for patients with CVD who also take beta blockers. Finally, given that some important confounders (such as comorbidities) have not been adjusted for in the included studies, the true association between ACEI/ARB use and the risk of hospitalization could not be well inferred.

Conclusion

In conclusion, ACEI/ARB use does not affect the risk and severity of COVID-19 infection and actually leads to a decreased mortality from COVID-19. The effect of ACEI/ARB use on hospitalization needs to be further assessed with adjusting for potential confounders. The potential protective role of ACEI/ARB supports the recommendation that these agents should not be discontinued for COVID-19 patients if they are already on them.

6. Acknowledgements

Guangbo Qu and Chenyu Sun contributed to the study design, the development of research protocol, and supervision of whole steps of this study. Liqin Shu designed the search strategy and conducted the literature search. Guangbo Qu and Liqin Shu conducted study selection, data extraction and quality assessment of included studies. Chenyu Sun checked the literature search and data extraction. Guangbo Qu performed data analyses and created tables and figures. Guangbo Qu and Chenyu Sun took responsibility for the interpretation of results. Guangbo Qu wrote the first draft of manuscript. Liqin Shu, Evelyn J. Song, Ce Cheng,

medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Dhiran Verghese, John Patrick Uy, Qin Zhou, Hongru Yang, Zhichun Guo, Chenyu Sun contributed to the edition and revision of the draft of manuscript. All authors reviewed and approved final version of the manuscript.

.

7. Funding

This study is financially supported by Hunan Provincial Key Laboratory of Clinical Epidemiology. (2020ZNDXLCL002)

8. Disclosure of interest

The authors have no interest to disclosure.

Reference

[1] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med* 2020; 382: 727-733.

[2] Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. *Am J Physiol Endocrinol Metab* 2020; 318: E736-E741.

[3] World Health Organization. Coronavirus disease 2019 (COVID-19). Situation report – 135. Geneva, Switzerland: World Health Organization; June 3, 2020. Available online:

medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200603-covid-19-sitrep-135.pdf?sfvrsn=39972feb_2

[4] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and Clinical Characteristics of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: A Descriptive Study. *Lancet* 2020; 395: 507-513.

[5] Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, Bi Z, Zhao Y. Prevalence and Impact of Cardiovascular Metabolic Diseases on COVID-19 in China. *Clin Res Cardiol* 2020; 109: 531-538.

[6] Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, Liu XQ, Chen RC, Tang CL, Wang T, Ou CQ, Li L, Chen PY, Sang L, Wang W, Li JF, Li CC, Ou LM, Cheng B, Xiong S, Ni ZY, Xiang J, Hu Y, Liu L, Shan H, Lei CL, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Cheng LL, Ye F, Li SY, Zheng JP, Zhang NF, Zhong NS, He JX, China Medical Treatment Expert Group for COVID-19. Comorbidity and Its Impact on 1590 Patients With COVID-19 in China: A Nationwide Analysis. *Eur Respir J* 2020; 55: 2000547.

[7] Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI, Gallagher PE. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. *Circulation* 2005; 111: 2605-2610.

[8] Yang G, Tan Z, Zhou L, Yang M, Peng L, Liu J, Cai JL, Yang R, Han J, Huang Y, He S.

medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Effects Of ARBs And ACEIs On Virus Infection, Inflammatory Status And Clinical Outcomes In COVID-19 Patients With Hypertension: A Single Center Retrospective Study. *Hypertension* 2020; 76: 51-58. doi: 10.1161/HYPERTENSIONAHA.120.15143.

[9] Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. *Nature* 2003; 426: 450-454.

[10] Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19. *N Engl J Med* 2020 May 1. doi: 10.1056/NEJMoa2006923. [Epub ahead of print].

[11] Diaz JH. Hypothesis: Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers May Increase the Risk of Severe COVID-19. *J Travel Med* 2020 Mar 18. doi: 10.1093/jtm/taaa041. Online ahead of print.

[12] Fang L, Karakiulakis G, Roth M. Are Patients With Hypertension and Diabetes Mellitus at Increased Risk for COVID-19 Infection? *Lancet Respir Med* 2020; 8: e21.

[13] G O'Mara. Could ACE inhibitors, and particularly ARBs, Increase susceptibility to COVID-19 infection? *BMJ* 2020; 368: m406.

[14] Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009; 6: e1000097.

[15] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol* 2010; 25: 603-605.

medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

[16] Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003; 327: 557-560.

[17] Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002; 21: 1539-1558.

[18] Li J, Wang X, Chen J, Zhang H, Deng A. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. *JAMA Cardiol* 2020 Apr 23. doi: 10.1001/jamacardio.2020.1624. [Epub ahead of print].

[19] Mehta N, Kalra A, Nowacki AS, Anjewierden S, Han Z, Bhat P, Carmona-Rubio AE, Jacob M, Procop GW, Harrington S, Milinovich A, Svensson LG, Jehi L, Young JB, Chung MK. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol* 2020 May 5. doi: 10.1001/jamacardio.2020.1855. [Epub ahead of print].

[20] Peng YD, Meng K, Guan HQ, Leng L, Zhu RR, Wang BY, He MA, Cheng LX, Huang K, Zeng QT. [Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV]. *Zhonghua Xin Xue Guan Bing Za Zhi* 2020; 48: E004. [Article in Chinese]

[21] Huang Z, Cao J, Yao Y, Jin X, Luo Z, Xue Y, Zhu C, Song Y, Wang Y, Zou Y, Qian J, Yu K, Gong H, Ge J. The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension. *Ann Transl Med* 2020; 8: 430.

medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

[22] Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, Liu YM, Zhao YC, Huang X, Lin L, Xia M, Chen MM, Cheng X, Zhang X, Guo D, Peng Y, Ji YX, Chen J, She ZG, Wang Y, Xu Q, Tan R, Wang H, Lin J, Luo P, Fu S, Cai H, Ye P, Xiao B, Mao W, Liu L, Yan Y, Liu M, Chen M, Zhang XJ, Wang X, Touyz RM, Xia J, Zhang BH, Huang X, Yuan Y, Rohit L, Liu PP, Li H. Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19. *Circ Res* 2020; 126: 1671-1681.

[23] Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, Hausvater A, Newman JD, Berger JS, Bangalore S, Katz SD, Fishman GI, Kunichoff D, Chen Y, Ogedegbe G, Hochman JS. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19. *N Engl J Med* 2020 May 1. doi: 10.1056/NEJMoa2008975. [Epub ahead of print].

[24] Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, Xiong W, Yang D, Chen R, Lu F, Lu Y, Liu X, Chen Y, Li X, Li Y, Summah HD, Lin H, Yan J, Zhou M, Lu H, Qu J. COVID-19 with Different Severity: A Multicenter Study of Clinical Features. *Am J Respir Crit Care Med* 2020; 201: 1380-1388.

[25] Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, Yang R, Di W, Wang Z, Li Z, Gao H, Liu L, Zhang G. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. *Emerg Microbes Infect* 2020; 9: 757-760.

[26] de Abajo FJ, Rodríguez-Martín S, Lerma V, Mejía-Abril G, Aguilar M, García-Luque A, Laredo L, Laosa O, Centeno-Soto GA, Gálvez MA, Puerro M, González-Rojano E,

medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Pedraza L, de Pablo I, Abad-Santos F, Rodríguez-Mañas L, Gil M, Tobías A, Rodríguez-Miguel A, Rodríguez-Puyol D, MED-ACE2-COVID19 study group. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. *Lancet* 2020; 395: 1705-1714.

[27] Zeng Z, Sha T, Zhang Y, Wu F, Hu H, Li H, Han J, Song W, Huang Q, Chen Z. Hypertension in patients hospitalized with COVID-19 in Wuhan, China: A single-center retrospective observational study. *medRxiv preprint* 2020. doi: 10.1101/2020.04.06.20054825.

[28] Bean D, Kraljevic Z, Searle T, Bendayan R, Pickles A, Folarin A, Roguski L, Noor K, Shek A, o'gallagher K, Zakeri R, Shah A, Teo J, Dobson RJB. ACE-inhibitors and Angiotensin-2 Receptor Blockers are not associated with severe SARS- COVID19 infection in a multi-site UK acute Hospital Trust. *medRxiv preprint* 2020. doi: 10.1101/2020.04.07.20056788.

[29] Rentsch CT, Kidwai-Khan F, Tate JP, Park LS, King Jr JT, Skanderson M, Hauser RG, Schultze A, Jarvis CI, Holodniy M, Re III VL, Akgun KM, Crothers K, Taddei TH, Freiberg MS, Justice AC. Covid-19 Testing, Hospital Admission, and Intensive Care Among 2,026,227 United States Veterans Aged 54-75 Years. *medRxiv preprint* 2020. doi: 10.1101/2020.04.09.20059964.

[30] Giorgi Rossi P, Marino M, Formisano D, Venturelli F, Vicentini M, Grilli R, The Reggio Emilia COVID-19 Working Group. Characteristics and outcomes of a cohort of SARS-CoV-2 patients in the Province of Reggio Emilia, Italy. *medRxiv preprint* 2020.

medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

doi: 10.1101/2020.04.13.20063545.

[31] Spiegeleer AD, Bronselaer A, Teo JT, Byttebier G, Tre GD, Belmans L, Dobson R, Wynendaele E, Van De Wiele C, Vandaele F, Van Dijck D, Bean D, Fedson D, Spiegeleer BD. The effects of ARBs, ACEIs and statins on clinical outcomes of COVID-19 infection among nursing home residents. *medRxiv preprint* 2020. doi: 10.1101/2020.05.11.20096347.

[32] Khera R, Clark C, Lu Y, Guo Y, Ren S, Truax B, Spatz ES, Murugiah K, Lin Z, Omer SB, Vojta D, Krumholz HM. Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers with the Risk of Hospitalization and Death in Hypertensive Patients with Coronavirus Disease-19. *medRxiv preprint* 2020. doi: 10.1101/2020.05.17.20104943.

[33] Liu Y, Huang F, Xu J, Yang P, Qin Y, Cao M, Wang Z, Li X, Zhang S, Ye L, Lv J, Wei J, Xie T, Gao H, Xu KF, Wang F, Liu L, Jiang C. Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients. *medRxiv preprint* 2020. doi: 10.1101/2020.03.20.20039586.

[34] Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, the Northwell COVID-19 Research Consortium; Barnaby DP, Becker LB, Chelico JD, Cohen SL, Cookingham J, Coppa K, Diefenbach MA, Dominello AJ, Duer-Hefele J, Falzon L, Gitlin J, Hajizadeh N, Harvin TG, Hirschwerk DA, Kim EJ, Kozel ZM, Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos TP. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the

medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

New York City Area. *JAMA* 2020; 323: 2052-2059.

[35] Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, Wang H, Wan J, Wang X, Lu Z. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol* 2020; e201017.

[36] Yan H, Valdes AM, Vijay A, Wang S, Liang L, Yang S, Wang H, Tan X, Du J, Jin S, Huang K, Jiang F, Zhang S, Zheng N, Hu Y, Cai T, Aithal GP. Role of Drugs Affecting the Renin-Angiotensin-Aldosterone System on Susceptibility and Severity of COVID-19: A Large Case-Control Study from Zheijang Province, China. *medRxiv preprint* 2020. doi: 10.1101/2020.04.24.20077875.

[37] Ip A, Parikh K, Parrillo JE, Mathura S, Hansen E, Sawczuk IS, Goldberg SL. Hypertension and Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. *medRxiv preprint* 2020. doi: 10.1101/2020.04.24.20077388.

[38] Soler MJ, Barrios C, Oliva R, Batlle D. Pharmacologic modulation of ACE2 expression. *Curr Hypertens Rep* 2008; 10: 410-414.

[39] Burchill LJ, Velkoska E, Dean RG, Griggs K, Patel SK, Burrell LM. Combination Renin-Angiotensin System Blockade and Angiotensin-Converting Enzyme 2 in Experimental Myocardial Infarction: Implications for Future Therapeutic Directions. *Clin Sci (Lond)* 2012; 123: 649-658.

[40] Rico-Mesa JS, White A, Anderson AS. Outcomes in Patients With COVID-19 Infection Taking ACEI/ARB. *Curr Cardiol Rep*, 202; 22: 31.

[41] Wang B, Li R, Lu Z, Huang Y. Does Comorbidity Increase the Risk of Patients With

medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

COVID-19: Evidence From Meta-Analysis. *Aging (Albany NY)* 2020; 12: 6049-6057.

[42] Mantovani A, Beatrice G, Dalbeni A. Coronavirus Disease 2019 and Prevalence of Chronic Liver Disease: A Meta-Analysis. *Liver Int* 2020 Apr 4. doi: 10.1111/liv.14465.

[43] Doulton TW. ACE inhibitor-angiotensin receptor blocker combinations: a clinician's perspective. *Mini Rev Med Chem* 2006; 6: 491-497.

[44] Rico-Mesa JS, White A, Anderson AS. Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB. *Curr Cardiol Rep* 2020; 22: 31. doi:10.1007/s11886-020-01291-4.

[45] Quartuccio L, Sonaglia A, McGonagle D, Fabris M, Peghin M, Pecori D, Monte AD, Bove T, Curcio F, Bassi F, Vita SD, Tascini C. Profiling COVID-19 Pneumonia Progressing Into the Cytokine Storm Syndrome: Results From a Single Italian Centre Study on Tocilizumab Versus Standard of Care. *J Clin Virol* 2020; 104444. doi: 10.1016/j.jcv.2020.104444.

[46] Wang X, Khaidakov M, Ding Z, Mitra S, Lu J, Liu S, Mehta JL. Cross-talk between inflammation and angiotensin II: studies based on direct transfection of cardiomyocytes with AT1R and AT2R cDNA. *Exp Biol Med* 2012; 237: 1394-1401.

[47] Liu J, Zhang PS, Yu Q, Liu L, Yang Y, Guo FM, Qiu HB. Losartan inhibits conventional dendritic cell maturation and Th1 and Th17 polarization responses: Novel mechanisms of preventive effects on lipopolysaccharide-induced acute lung injury. *Int J Mol Med* 2012; 29: 269-276.

[48] Aref A. Abdulhak B, Kashour T, Noman A, Tlayjeh H, Mohsen A, Al-Mallah MH, Tleyjeh IM. Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor

medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Blockers and Outcome of COVID-19 : A Systematic Review and Meta-analysis. *medRxiv preprint* 2020. doi: 10.1101/2020.05.06.20093260.

[49] Zhang X, Yu J, Pan L, Jiang HY. ACEI/ARB Use and Risk of Infection or Severity or Mortality of COVID-19: A Systematic Review and Meta-analysis. Pharmacol Res 2020 May 15: 104927. doi: 10.1016/j.phrs.2020.104927.

[50] Ghosal S, Mukherjee Jagat J, Sinha B, Gangopadhyay KK. The effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on death and severity of disease in patients with coronavirus disease 2019 (COVID-19): A meta-analysis. *medRxiv preprint* 2020. doi: 10.1101/2020.04.23.20076661.

[51] American Heart Association (AHA), Heart Failure Society of America (HFSA) and American College of Cardiology (ACC). Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician. 2020.

[52] Wang Y, Moreira Mda C, Heringer-Walther S, Schultheiss HP, Siems WE, Wessel N, Walther T. Beta blockers prevent correlation of plasma ACE2 activity with echocardiographic parameters in patients with idiopathic dilated cardiomyopathy. *J Cardiovasc Pharmaco*l 2015; 65: 8-12.

Figure legends

medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 1. Flow diagram of study selection for this systematic review and meta-analysis.

Figure 2. Pooled results of meta-analyses for the association between ACEI/ARB use and risk of COVID-19 infection. (A) Pooled crude OR for the comparison between ACEI use versus non-ACEI use; (B) Pooled crude OR for the comparison between ARB use versus non-ARB use; (C) Pooled crude OR for the comparison between ACEI/ARB use versus non-ACEI/ARB use; (D) Pooled adjusted OR for the comparison between ACEI use versus non-ACEI use; (E) Pooled adjusted OR for the comparison between ARB use versus non-ARB use; (F) Pooled adjusted OR for the comparison between ACEI/ARB use versus non-ACEI/ARB use.

Figure 3. Pooled results of meta-analyses for the association between ACEI/ARB use and risk of hospital admission for COVID-19. (A) Pooled adjusted OR for the comparison between ACEI use versus non-ACEI use; (B) Pooled adjusted OR for the comparison between ARB use versus non-ARB use; (C) Pooled adjusted OR for the comparison between ACEI/ARB use versus non-ACEI/ARB use.

Figure 4. Pooled results of meta-analyses for the association between ACEI/ARB use and risk of severity of COVID-19 infection. (A) Pooled crude OR for the comparison between ACEI use versus non-ACEI use; (B) Pooled crude OR for the comparison between ARB use versus non-ARB use; (C) Pooled crude OR for the comparison between ACEI/ARB use versus non-ACEI/ARB use; (D) Pooled adjusted OR for the comparison between ACEI use versus non-ACEI use; (E) Pooled adjusted OR for the comparison between ARB use versus non-ARB use; (F) Pooled adjusted OR for the comparison between ACEI/ARB use versus

medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

non-ACEI/ARB use.

Figure 5. Pooled results of meta-analyses for the association between ACEI/ARB use and risk of death from COVID-19. (A) Pooled crude OR for the comparison between ACEI/ARB use versus non-ACEI/ARB use; (B) Pooled adjusted OR for the comparison between ACEI/ARB use versus non-ACEI/ARB use.

Tables

Table 1. Characteristics of included studies.

Table 2. Meta-analysis on the association between ACEI/ARB use and risk of infection, hospital admission, severity, and death of COVID-19.

medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Table 1. Characteristics of included studies.

First author	Year	Region	Race	Study design	Total	ACEI/ARB exposure	Non-ACEI/ARB exposure	Age (years)	Male/Female	Diagnostic criteria of COVID-19	Comorbidity	Comparison groups	Reported association outcome	Quality
Li J [18]	2020	China	Asian	Retrospective cohort	362	115	247	66.0 (59.0-73.0)	189/173	The diagnosis and treatment scheme for COVID-19 of Chinese (5th edition).	Hypertension (100%); Cerebrovascular disease (18.8%); Coronary heart disease(17.1%) ; Heart failure(2.8%); Diabetes (35.1%); Digestive disorder(21.5%); Respiratory disease(5.0%); Neurological disease(10.5%); Solid tumor(3.0%); Chronic renal disease(9.7%)	ACEI vs Non–ACEI; ARB vs Non–ARB; ACEI vs Other drugs; ARB vs Other drugs ACEI vs ARB ACEI/ARB vs Non–ACEI/ARB	Severity and death risk	Moderate
Mehta N[19]	2020	United States	Mixed	Retrospective cohort	18,472	2,285	16,187	49±21	7384/12725	Laboratory testing using RT-PCR	Diabetes(n=86); Coronary artery disease(n=58); Hypertension (n=186); Chronic obstructive pulmonary disease (n=46); Heart failure (n=52)	ACEI vs Non–ACEI; ARB vs Non–ARB; ACEI/ARB vs Non–ACEI/ARB	Infection and death risk	Moderate
Peng YD [20]	2020	China	Asian	Retrospective cohort	112	22	90	62.0 (55.0-67.0)	53/59	The diagnosis and treatment scheme for COVID-19 of Chinese (5th edition).	Hypertension (82.1%);Coronary heart disease (55.4%); Heart failure (35.7%); Diabetse (20.5%)	ACEI/ARB vs Non–ACEI/ARB	Death risk	Moderate
Huang Z [21]	2020	China	Asian	Retrospective cohort	50	20	30	52.65±13.12 for ACEI/ARB exposure; 67.77±12.84 for Non-ACEI/ARB exposure	27/23	The diagnosis and treatment scheme for COVID-19 of Chinese (6th edition).	Diabetes(8.0%); Coronary heart disease(2.0%); Chronic obstructive pulmonary disease(2.0%); Anemia (2.0%)	ACEI/ARB vs Non–ACEI/ARB	Severity and death risk	Moderate

medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Zhang P [22]	2020	China	Asian	Retrospective cohort	1128	118	940	64 (55-68) for ACEI/ARB exposure; 64 (57-69) for Non-ACEI/ARB exposure	603/525	New Coronavirus Pneumonia Prevention and Control Program (5th edition) published by the National Health Commission of China and WHO interim guidance	Hypertension (100%); Diabetes (n=244); Coronary heart disease (n=131); Chronic renal diseases (n=35); Cerebrovascular diseases (n=41); Chronic liver disease (n=21); Chronic obstructive pulmonary disease (n=6)	ACEI/ARB vs Non–ACEI/ARB	Death risk	High
Yang G [8]	2020	China	Asian	Retrospective cohort	126	43	83	65 (57-72) for ACEI/ARB exposure; 67 (62-75) for non-ACEI/ARB exposure	62/64	The Fifth Trial Version of the Chinese National Health Commission	Hypertension (100%); Diabetes (30.2%); Respiratory disease (4.7%); Kidney disease (2.4%); Hepatic disease (6.3%); Cardiopathy (18.3%); Neurological disease (7.9%)	ACEI/ARB vs Non–ACEI/ARB	Severity and death risk	High
Mancia G [10]	2020	Italy	NA	Case-control	37031	8071 for ACEI; 7304 for ARB	NA	NA	23371/13660	Positive nasopharyngeal swab specimens tested with at least two real-time reverse-transcriptase–polymerase-chain-reaction assays targeting different genes of SARSCov-2.	Cardiovascular disease (23.1%); Respiratory disease (6.4%); Kidney disease (3.0%); Cancer (15.5%)	ACEI vs Non–ACEI; ARB vs Non–ARB;	Infection risk	High

medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Reynolds HR [23]	2020	United States	Mixed	Retrospective cohort	12,594	1044 for ACEI; 1328 for ARB; 2319 for ACEI or ARB	NA	49 (34–63)	5229/7365	A series of SARS-CoV-2 RNA test	Hypertension (34.6%); Heart failure (6.2%); myocardial infarction (4.2%); Diabetes (18.0%); Chronic kidney disease (9.6%); Obstructive lung disease (14.6%)	ACEI vs Non–ACEI; ARB vs Non–ARB; ACEI/ARB vs Non–ACEI/ARB	Infection risk	High
Feng Y [24]	2020	China	Asian	Retrospective cohort	476	8 for ACEI; 27 for ARB; 33 for ACEI or ARB	NA	53(40-64)	271/205	The diagnosis and treatment scheme for COVID-19 of Chinese (5th edition).	Hypertension (23.7%); Cardiovascular disease (8.0%); Diabetes (10.3%); Malignancy (2.5%); Cerebrovascular disease (3.6%); Immunosuppression (1.5%); COPD (4.6%); Chronic nephropathy (0.8%); Others (21.6%)	ACEI vs Non–ACEI; ARB vs Non–ARB; ACEI/ARB vs Non–ACEI/ARB	Severity risk	Moderate
Meng J [25]	2020	China	Asian	Retrospective cohort	42	17	25	64.5 (55.8–69.0)	24/18	The guidelines established by the National Health Commission of the People's Republic of China.	Hypertension (100%); other comorbidities (not reported)	ACEI/ARB vs Non–ACEI/ARB	Death risk	Moderate
de Abajo FJ [26]	2020	Spain	NA	Case-control	12529	2432 for ACEI; 1860 for ARB	NA	75.3±12.3	7645/4884	a PCR-confirmed diagnosis of COVID-19	Hypertension (50.0%); Diabetes (20.9%); Dyslipidaemia (31.7%); Ischaemic heart disease (7.8%); Heart failure (3.8%); Atrial fibrillation (8.8%); Thromboembolic disease (2.7%); Cerebrovascular accident (5.1%); COPD (8.3%); Asthma (5.7%); Cancer (14.2%); Chronic renal failure (5.3%)	ACEI vs Non–ACEI; ARB vs Non–ARB	Infection risk	High
Zeng Z [27]	2020	China	Asian	Retrospective cohort	75	28	47	67±11	35/40	the criteria of COVID-19 previously established by the WHO	Hypertension (100%)	ACEI/ARB vs Non–ACEI/ARB	Infection, severity and death risk	Moderate

medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Bean DM [28]	2020	United Kingdom	Mixed	Retrospective cohort	1200	399	801	67.96 ±17.07	686/514	NA	Hypertension (53.8%); Diabetes(34.8%); HF(8.9%); IHD(13.3%); COPD(10.1%); Asthma(14.1%); CKD(17.2%); Stroke/TIA(19.6%)	ACEI/ARB vs Non–ACEI/ARB	Death risk	High
Rentsch CT[29]	2020	United States	Mixed	Retrospective cohort	3789	1011 for ACEI; 563 for ARB; 1532 for ACEI or ARB	2778 for Non-ACEI; 3226 for Non-ARB; 2257 for Non-ACEI or ARB	65.7 (60.5-70.7)	3417/372	PCR tested positive for SARS-CoV-2	Asthma (7.5%); Cancer(15.1%); Chronic kidney disease (14.8%); COPD(26.2%); Diabetes (32.8%); Hypertension (65.0%); Liver disease (12.3%); Vascular disease (28.9%)	ACEI/ARB vs Non–ACEI/ARB	Infection, Hospitalization and ICU risk	High
Giorgi Rossi P[30]	2020	Italy	NA	Retrospective cohort	2653	NA	NA	All age group	1328/1325	all symptomatic patients who tested positive with PCR	NA	ACEI vs Non–ACEI	Hospitalization and death risk	High
Spiegeleer AD [31]	2020	Belgium	NA	Retrospective cohort	154	30	124	86±7	51/103	clinical grounds and/or PCR lab testing	Hypertension (25.3%); Diabetes(18.2%)	ACEI/ARB vs Non–ACEI/ARB	Infection and severity risk	High
Khera R [32]	2020	United States	Mixed	Retrospective cohort	10196	3083 for ACEI; 2957 for ARB	NA	≥18	4675/5521	PCR tested positive for SARS-CoV-2	Hypertension (100%)	ACEI vs Others; ARB vs Others; ACEI vs ARB	Hospitalization and death risk	High
Liu Y [33]	2020	China	Asian	Retrospective cohort	46	2 for ACEI; 10 for ARB	NA	>65	NA	The diagnosis and treatment scheme for COVID-19 of Chinese	Hypertension (100%)	ACEI vs Non–ACEI; ARB vs Non–ARB	Severity risk	Moderate

medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Richardson S [34]	2020	United States	Mixed	Retrospective cohort	5700	168 for ACEI; 245 for ARB; 413 for ACEI or ARB	953	63(52-75)	3437/2263	PCR tested positive for SARS-CoV-2	Hypertension (56.6%); Coronary artery disease(11.1%); COPD(5.4%); Cancer (6%)	ACEI/ARB vs Non–ACEI/ARB	Death risk	High
Guo T [35]	2020	China	Asian	Retrospective cohort	187	19 for ACEI or ARB	168 for Non-ACEI or ARB	58.50±14.66	91/96	The interim guidance of theWorldHealth Organization	Hypertension (32.6%); CHD (11.2%); Cardiomyopathy(4.3%); Diabetes(15.0%); COPD (2.1%); Malignant neoplasm (7.0%); Chronic kidney disease (3.2%)	ACEI/ARB vs Non–ACEI/ARB	Death risk	High
Yan H [36]	2020	China	Asian	Case-control	49,277	5for ACEI; 53 for ARB; 58 for ACEI or ARB	NA	48.75±14.19	23817/25460	The diagnosis and treatment scheme for COVID-19 of Chinese (5th edition).	Diabetes(6.14%); Hypertension (20.28%); Cardio or cerebrovascular disease (1.3%); Tumour (2.0%)	ACEI vs Non–ACEI; ARB vs Non–ARB	Infection and severity risk	High
Andrew Ip [37]	2020	United States	NA	Retrospective cohort	1129	460 for ACEI or ARB	669 for Non-ACEI or ARB	NA	NA	NA	Hypertension (100%)	ACEI/ARB vs Non–ACEI/ARB	Death risk	Moderate

medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Table 2. Meta-analysis on the association between ACEI/ARB use and risk of infection, hospital admission, severity, and death of COVID-19.

Subgroup	Number of studies	Crude OR	95%CI		P	I2(%)	Model	Number of studies	Adjusted OR	95%CI		P	I2(%)	Model
Subgroup Analysis for Risk of Infection														
ACEI use vs non-ACEI use														
Overall	4	1.27	0.95	1.69	0.103	91.9	R	4	0.94	0.87	1.01	0.106	0	F
Study design														
Case-control	2	1.16	1.08	1.24	<0.001	12.2	F	2	0.96	0.86	1.06	0.381	0	F
Cohort	2	1.44	0.92	2.24	0.108	93.0	R	2	0.91	0.8	1.03	0.139	0	F
Region														
China	1	0.72	0.3	1.72	0.461	NA	NA	1	0.65	0.27	1.6	0.348	NA	NA
Italy	1	1.16	1.08	1.24	<0.001	NA	NA	1	0.96	0.87	1.07	0.439	NA	NA
United States	2	1.44	0.92	2.24	0.108	93.0	R	2	0.91	0.8	1.03	0.139	0	F
Race														
Asian	1	0.72	0.3	1.72	0.461	NA	NA	1	0.65	0.27	1.6	0.348	NA	NA
Mixed	2	1.44	0.92	2.24	0.108	93.0	R	2	0.91	0.8	1.03	0.139	0	F
Unknown	1	1.16	1.08	1.24	<0.001	NA	NA	1	0.96	0.87	1.07	0.439	NA	NA
Quality														
High	4	1.27	0.95	1.69	0.103	91.9	R	3	0.94	0.87	1.03	0.192	0	F
Moderate	0	NA	NA	NA	NA	NA	NA	1	0.89	0.72	1.10	0.281	NA	NA
ARB use vs non-ARB use														
Overall	4	1.07	0.76	1.50	0.709	95.7	R	4	0.73	0.49	1.09	0.120	95.1	R

medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Study design														
Case-control	2	0.80	0.35	1.81	0.59	97.0	R	2	0.48	0.13	1.86	0.289	98.2	R
Cohort	2	1.40	0.93	2.10	0.107	89.5	R	2	1.03	0.91	1.16	0.688	0	F
Region														
China	1	0.52	0.40	0.68	<0.001	NA	NA	1	0.24	0.17	0.34	<0.001	NA	NA
Italy	1	1.20	1.12	1.29	<0.001	NA	NA	1	0.95	0.86	1.05	0.314	NA	NA
United States	2	1.40	0.93	2.10	0.107	89.5	R	2	1.03	0.91	1.16	0.688	0	F
Race														
Asian	1	0.52	0.40	0.68	<0.001	NA	NA	1	0.24	0.17	0.34	<0.001	NA	NA
Mixed	2	1.40	0.93	2.10	0.107	89.5	R	2	1.03	0.91	1.16	0.688	0	F
Unknown	1	1.20	1.12	1.29	<0.001	NA	NA	1	0.95	0.86	1.05	0.314	NA	NA
Quality														
High	4	1.07	0.76	1.50	0.709	95.7	R	3	0.64	0.38	1.06	0.083	96.6	R
Moderate	0	NA	NA	NA	NA	NA	NA	1	1.09	0.87	1.37	0.457	NA	NA
ACEI/ARB use vs non-ACEI/ARB use														
Overall	7	1.10	0.84	1.43	0.488	88.6	R	6	0.96	0.91	1.01	0.142	5.8	F
Study design														
Case-control	2	0.81	0.38	1.74	0.583	97.0	R	2	0.66	0.26	1.68	0.387	75.3	R
Cohort	5	1.31	0.96	1.77	0.089	71.8	R	3	0.97	0.89	1.05	0.425	0	F
Region														
China	3	0.75	0.47	1.21	0.241	70.2	R	1	0.36	0.14	0.93	0.035	NA	NA
United States	2	1.46	0.93	2.29	0.096	90.3	R	2	0.97	0.89	1.05	0.398	0	F
Belgium	1	1.52	0.64	3.61	0.343	NA	NA	1	2.72	0.42	17.74	0.296	NA	NA

medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Italy	1	1.18	1.12	1.24	<0.001	NA	NA	1	0.96	0.89	1.03	0.273	NA	NA
Race														
Asian	3	0.75	0.47	1.21	0.241	70.2	R	1	0.36	0.14	0.93	0.035	NA	NA
Mixed	2	1.46	0.93	2.29	0.096	90.3	R	4	0.97	0.89	1.05	0.425	0	F
Unknown	2	1.18	1.12	1.24	<0.001	0	F	1	0.96	0.89	1.03	0.273	NA	NA
Quality														
High	6	1.1	0.83	1.44	0.515	90.5	R	5	0.96	0.91	1.02	0.152	24.4	F
Moderate	1	1.15	0.39	3.37	0.799	NA	NA	1	0.97	0.81	1.16	0.733	NA	NA
Subgroup Analysis for Risk of Hospital Admission														
ACEI use vs non-ACEI use														
Overall	NA	NA	NA	NA	NA	NA	NA	3	1.29	1.07	1.57	0.009	62.4	R
Study design														
Case-control	NA	NA	NA	NA	NA	NA	NA	1	1.13	0.97	1.31	0.111	NA	NA
Cohort	NA	NA	NA	NA	NA	NA	NA	2	1.46	1.06	2.02	0.021	57.9	R
Region														
Italy	NA	NA	NA	NA	NA	NA	NA	1	1.30	1.11	1.52	0.001	NA	NA
United States	NA	NA	NA	NA	NA	NA	NA	1	1.84	1.22	2.78	0.004	NA	NA
Spain	NA	NA	NA	NA	NA	NA	NA	1	1.13	0.97	1.31	0.111	NA	NA
Race														
Mixed	NA	NA	NA	NA	NA	NA	NA	1	1.84	1.22	2.78	0.004	NA	NA
Unknown	NA	NA	NA	NA	NA	NA	NA	2	1.21	1.09	1.35	0.001	38.2	F
Quality														
High	NA	NA	NA	NA	NA	NA	NA	2	1.21	1.09	1.35	0.001	38.2	F

medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Moderate	NA	NA	NA	NA	NA	NA	NA	1	1.84	1.22	2.78	0.004	NA	NA
ARB use vs non-ARB use														
Overall	NA	NA	NA	NA	NA	NA	NA	2	1.69	1.46	1.96	<0.001	0	F
Study design														
Case-control	NA	NA	NA	NA	NA	NA	NA	1	1.70	1.46	1.99	<0.001	NA	NA
Cohort	NA	NA	NA	NA	NA	NA	NA	1	1.61	1.04	2.50	0.033	NA	NA
Region														
United States	NA	NA	NA	NA	NA	NA	NA	1	1.61	1.04	2.50	0.033	NA	NA
Spain	NA	NA	NA	NA	NA	NA	NA	1	1.70	1.46	1.99	<0.001	NA	NA
Race														
Mixed	NA	NA	NA	NA	NA	NA	NA	1	1.61	1.04	2.50	0.033	NA	NA
Unknown	NA	NA	NA	NA	NA	NA	NA	1	1.70	1.46	1.99	<0.001	NA	NA
Quality														
High	NA	NA	NA	NA	NA	NA	NA	1	1.70	1.46	1.99	<0.001	NA	NA
Moderate	NA	NA	NA	NA	NA	NA	NA	1	1.61	1.04	2.5	0.033	NA	NA
ACEI/ARB use vs non-ACEI/ARB use														
Overall	NA	NA	NA	NA	NA	NA	NA	4	1.38	1.21	1.57	<0.001	34.5	F
Study design														
Case-control	NA	NA	NA	NA	NA	NA	NA	1	1.39	0.93	2.07	0.107	NA	NA
Cohort	NA	NA	NA	NA	NA	NA	NA	3	1.45	1.11	1.88	0.006	56.3	R
Region														
United States	NA	NA	NA	NA	NA	NA	NA	2	1.59	1.03	2.44	0.035	57.7	R
Spain	NA	NA	NA	NA	NA	NA	NA	1	1.39	0.93	2.07	0.107	NA	NA

medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Italy	NA	NA	NA	NA	NA	NA	NA	1	1.30	1.11	1.52	0.001	NA	NA
Race														
Mixed	NA	NA	NA	NA	NA	NA	NA	2	1.59	1.03	2.44	0.035	57.7	R
Unknown	NA	NA	NA	NA	NA	NA	NA	2	1.31	1.14	1.52	<0.001	0	F
Quality														
High	NA	NA	NA	NA	NA	NA	NA	3	1.31	1.14	1.50	<0.001	0	F
Moderate	NA	NA	NA	NA	NA	NA	NA	1	1.93	1.38	2.71	<0.001	NA	NA
Subgroup Analysis for Risk of Severity														
ACEI use vs non-ACEI use														
Overall	5	1.01	0.63	1.60	0.982	75.3	R	2	0.90	0.72	1.14	0.939	0	F
Study design														
Case-control	1	0.91	0.69	1.21	0.510	NA	NA	1	0.90	0.71	1.14	0.374	NA	NA
Cohort	4	0.99	0.51	1.90	0.964	60.7	R	1	1.23	0.19	7.95	0.828	NA	NA
Region														
China	3	0.73	0.40	1.33	0.308	0	F	1	1.23	0.19	7.95	0.828	NA	NA
Italy	1	0.91	0.69	1.21	0.510	NA	NA	0	NA	NA	NA	NA	NA	NA
United States	1	1.63	1.34	1.99	0.001	NA	NA	1	0.90	0.71	1.14	0.374	NA	NA
Race														
Asian	3	0.73	0.4	1.33	0.308	0	F	1	1.23	0.19	7.95	0.828	NA	NA
Mixed	1	1.63	1.34	1.99	0.001	NA	NA	1	0.90	0.71	1.14	0.374	NA	NA
Unknown	1	0.91	0.69	1.21	0.510	NA	NA	0	NA	NA	NA	NA	NA	NA
Quality														

medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

High	2	1.34	1.14	1.58	<0.001	91.0	R	2	0.90	0.72	1.14	0.939	0	F
Moderate	3	0.73	0.4	1.33	0.308	0	F	0	NA	NA	NA	NA	NA	NA
ARB use vs non-ARB use														
Overall	5	0.75	0.41	1.39	0.090	91.8	R	3	0.91	0.74	1.13	0.409	45.8	F
Study design														
Case-control	1	0.83	0.63	1.10	0.190	NA	NA	1	0.77	0.36	1.64	0.498	NA	NA
Cohort	4	0.70	0.29	1.69	0.427	91.8	R	2	0.59	0.17	2.09	0.413	71.2	R
Region														
China	3	0.48	0.16	1.50	0.206	86.9	R	2	0.60	0.31	1.16	0.723	NA	NA
Italy	1	0.83	0.63	1.10	0.190	NA	NA	1	0.96	0.77	1.20	0.128	48.1	F
United States	1	1.76	1.47	2.10	<0.001	NA	NA	0	NA	NA	NA	NA	NA	NA
Race														
Asian	3	0.48	0.16	1.50	0.206	86.9	R	2	0.60	0.31	1.16	0.723	NA	NA
Mixed	1	1.76	1.47	2.10	<0.001	NA	NA	1	0.96	0.77	1.20	0.128	48.1	F
Unknown	1	0.83	0.63	1.10	0.190	NA	NA	0	NA	NA	NA	NA	NA	NA
Quality														
High	2	1.22	0.58	2.54	0.599	95.0	R	2	0.94	0.76	1.17	0.594	0	F
Moderate	3	0.48	0.16	1.50	0.206	86.9	R	1	0.25	0.06	1.01	0.052	NA	NA
ACEI/ARB use vs non-ACEI/ARB use														
Overall	11	0.75	0.48	1.17	0.201	88.7	R	4	0.9	0.77	1.05	0.197	27.6	F
Study design														
Case-control	1	0.87	0.71	1.06	0.173	NA	NA	1	0.82	0.41	1.65	0.578	NA	NA
Cohort	10	0.72	0.41	1.27	0.255	87.0	R	3	0.62	0.27	1.38	0.239	50.8	R

medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Region														
China	8	0.61	0.34	1.09	0.093	73.8	R	2	0.53	0.17	1.63	0.269	55.0	R
United States	1	1.87	1.62	2.16	<0.001	NA	NA	1	0.93	0.79	1.09	0.377	NA	NA
Belgium	1	0.79	0.29	2.16	0.647	NA	NA	1	0.48	0.11	2.13	0.334	NA	NA
Italy	1	0.87	0.71	1.06	0.173	NA	NA	0	NA	NA	NA	NA	NA	NA
Race														
Asian	8	0.61	0.34	1.09	0.093	73.8	R	2	0.53	0.17	1.63	0.269	55.0	R
Mixed	1	1.87	1.62	2.16	<0.001	NA	NA	1	0.93	0.79	1.09	0.377	NA	NA
Unknown	2	0.87	0.71	1.06	0.154	0	F	1	0.48	0.11	2.13	0.334	NA	NA
Quality														
High	4	1.05	0.59	1.88	0.860	92.6	R	3	0.92	0.79	1.07	0.279	0	F
Moderate	7	0.59	0.30	1.17	0.129	77.5	R	1	0.25	0.06	1.01	0.052	NA	NA
Subgroup Analysis for Risk of Death														
ACEI use vs non-ACEI use														
Overall	2	0.51	0.19	1.38	0.185	74.6	R	2	0.52	0.15	1.82	0.307	93.8	R
Study design														
Case-control	0	NA	NA	NA	NA	NA	NA	0	NA	NA	NA	NA	NA	NA
Cohort	2	0.51	0.19	1.38	0.185	74.6	R	2	0.52	0.15	1.82	0.307	93.8	R
Region														
China	1	0.91	0.38	2.18	0.832	NA	NA	0	NA	NA	NA	NA	NA	NA
Italy	0	NA	NA	NA	NA	NA	NA	1	0.97	0.70	1.35	0.857	NA	NA
Multiple areas	1	0.33	0.20	0.54	<0.001	NA	NA	1	0.27	0.16	0.46	<0.001	NA	NA
Race														

medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Asian	1	0.91	0.38	2.18	0.832	NA	NA	0	NA	NA	NA	NA	NA	NA
Mixed	1	0.33	0.20	0.54	<0.001	NA	NA	1	0.27	0.16	0.46	<0.001	NA	NA
Unknown	0	NA	NA	NA	NA	NA	NA	1	0.97	0.70	1.35	0.857	NA	NA
Quality														
High	1	0.33	0.20	0.54	<0.001	NA	NA	2	0.52	0.15	1.82	0.307	93.8	R
Moderate	1	0.91	0.38	2.18	0.832	NA	NA	0	NA	NA	NA	NA	NA	NA
ARB use vs non-ARB use														
Overall	2	1.1	0.81	1.49	0.531	39.5	F	NA	NA	NA	NA	NA	NA	NA
Study design														
Case-control	0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Cohort	2	1.1	0.81	1.49	0.531	39.5	F	NA	NA	NA	NA	NA	NA	NA
Region														
China	1	0.77	0.41	1.44	0.412	NA	NA	NA	NA	NA	NA	NA	NA	NA
Multiple areas	1	1.23	0.87	1.74	0.242	NA	NA	NA	NA	NA	NA	NA	NA	NA
Race														
Asian	1	0.77	0.41	1.44	0.412	NA	NA	NA	NA	NA	NA	NA	NA	NA
Mixed	1	1.23	0.87	1.74	0.242	NA	NA	NA	NA	NA	NA	NA	NA	NA
Quality														
High	1	1.23	0.87	1.74	0.242	NA	NA	NA	NA	NA	NA	NA	NA	NA
Moderate	1	0.77	0.41	1.44	0.412	NA	NA	NA	NA	NA	NA	NA	NA	NA
ACEI/ARB use vs non-ACEI/ARB use														
Overall	11	0.87	0.66	1.15	0.322	57.0	R	5	0.51	0.31	0.84	0.009	78.4	R
Study design														

medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Case-control	0	NA	NA	NA	NA	NA	NA	0	NA	NA	NA	NA	NA	NA
Cohort	11	0.87	0.66	1.15	0.322	57.0	R	5	0.51	0.31	0.84	0.009	78.4	R
Region														
China	6	0.74	0.42	1.30	0.299	32.5	F	2	0.36	0.17	0.77	0.009	0	F
United States	3	1.05	0.61	1.82	0.866	85.6	R	0	NA	NA	NA	NA	NA	NA
United Kingdom	1	0.83	0.64	1.07	0.155	NA	NA	1	0.63	0.47	0.84	0.002	NA	NA
Multiple areas	1	0.65	0.18	2.34	0.510	NA	NA	1	0.27	0.16	0.46	<0.001	NA	NA
Italy	0	NA	NA	NA	NA	NA	NA	1	0.97	0.70	1.35	0.857	NA	NA
Race														
Asian	6	0.74	0.42	1.30	0.299	32.5	F	2	0.36	0.17	0.77	0.009	0	F
Mixed	4	1.06	0.76	1.50	0.719	56.9	R	2	0.43	0.19	0.97	0.043	86.8	R
Unknown	1	0.66	0.51	0.86	0.002	NA	NA	1	0.97	0.70	1.35	0.857	NA	NA
Quality														
High	5	0.88	0.59	1.34	0.571	75.9	R	5	0.51	0.31	0.84	0.009	78.4	R
Moderate	6	0.73	0.59	0.92	0.006	23.9	F	0	NA	NA	NA	NA	NA	NA

medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .


Identification
Screening
Selection
Inclusion
Records identified from five electronic database (n=471)
Records identified through other sources (n=6)
27 records were excluded for duplicated publications
Waiting for screening the title and abstract of articles (n=450)
391 records were excluded for irrelevant, review, or case report
Waiting for viewing the full-text of articles (n= 59)
37 records were excluded according to the study selection certia.
22 articles were included for systematic review and meta-analysis

A

Study or Subgroup	log[Odds Ratio]	SE	Weight	Odds Ratio IV, Random, 95% CI
Mancia G 2020	0.148	0.035	32.3%	1.16 [1.08, 1.24]
Rentsch CT 2020	0.582	0.065	30.9%	1.79 [1.58, 2.03]
Reynolds HR 2020	0.131	0.1	28.6%	1.14 [0.94, 1.39]
Yan H 2020	-0.329	0.445	8.2%	0.72 [0.30, 1.72]
Total (95% CI)			**100.0%**	**1.27 [0.95, 1.69]**

Heterogeneity: Tau² = 0.07; Chi² = 37.36, df = 3 (P < 0.00001); I² = 92%
Test for overall effect: Z = 1.62 (P = 0.10)



B

Study or Subgroup	log[Odds Ratio]	SE	Weight	Odds Ratio IV, Random, 95% CI
Mancia G 2020	0.182	0.036	26.8%	1.20 [1.12, 1.29]
Rentsch CT 2020	0.531	0.058	26.3%	1.70 [1.52, 1.91]
Reynolds HR 2020	0.113	0.122	23.9%	1.12 [0.88, 1.42]
Yan H 2020	-0.654	0.139	23.1%	0.52 [0.40, 0.68]
Total (95% CI)			**100.0%**	**1.07 [0.76, 1.50]**

Heterogeneity: Tau² = 0.11; Chi² = 70.07, df = 3 (P < 0.00001); I² = 96%
Test for overall effect: Z = 0.37 (P = 0.71)



C

Study or Subgroup	log[Odds Ratio]	SE	Weight	Odds Ratio IV, Random, 95% CI
Mancia G 2020	0.166	0.026	20.5%	1.18 [1.12, 1.24]
Rentsch CT 2020	0.157	0.089	18.9%	1.17 [0.98, 1.39]
Reynolds HR 2020	0.615	0.112	18.0%	1.85 [1.49, 2.30]
Spiegeleer AD 2020	0.419	0.442	6.4%	1.52 [0.64, 3.62]
Yan H 2020	-0.616	0.133	17.1%	0.54 [0.42, 0.70]
Yang G 2020	-0.062	0.192	14.5%	0.94 [0.65, 1.37]
Zeng Z 2020	0.14	0.548	4.6%	1.15 [0.39, 3.37]
Total (95% CI)			**100.0%**	**1.10 [0.84, 1.43]**

Heterogeneity: Tau² = 0.09; Chi² = 52.27, df = 6 (P < 0.00001); I² = 89%
Test for overall effect: Z = 0.69 (P = 0.49)



D

Study or Subgroup	log[Odds Ratio]	SE	Weight	Odds Ratio IV, Fixed, 95% CI
Mancia G 2020	-0.041	0.053	59.1%	0.96 [0.87, 1.06]
Mehta N 2020	-0.117	0.108	14.2%	0.89 [0.72, 1.10]
Reynolds HR 2020	-0.083	0.08	25.9%	0.92 [0.79, 1.08]
Yan H 2020	-0.431	0.459	0.8%	0.65 [0.26, 1.60]
Total (95% CI)			**100.0%**	**0.94 [0.86, 1.01]**

Heterogeneity: Chi² = 1.12, df = 3 (P = 0.77); I² = 0%
Test for overall effect: Z = 1.61 (P = 0.11)



E

Study or Subgroup	log[Odds Ratio]	SE	Weight	Odds Ratio IV, Random, 95% CI
Mancia G 2020	-0.051	0.051	26.6%	0.95 [0.86, 1.05]
Mehta N 2020	0.086	0.116	24.8%	1.09 [0.87, 1.37]
Reynolds HR 2020	0	0.074	26.1%	1.00 [0.86, 1.16]
Yan H 2020	-1.427	0.177	22.4%	0.24 [0.17, 0.34]
Total (95% CI)			**100.0%**	**0.73 [0.49, 1.08]**

Heterogeneity: Tau² = 0.15; Chi² = 61.42, df = 3 (P < 0.00001); I² = 95%
Test for overall effect: Z = 1.55 (P = 0.12)



F

Study or Subgroup	log[Odds Ratio]	SE	Weight	Odds Ratio IV, Fixed, 95% CI
Mancia G 2020	-0.041	0.053	59.1%	0.96 [0.87, 1.06]
Mehta N 2020	-0.117	0.108	14.2%	0.89 [0.72, 1.10]
Reynolds HR 2020	-0.083	0.08	25.9%	0.92 [0.79, 1.08]
Yan H 2020	-0.431	0.459	0.8%	0.65 [0.26, 1.60]
Total (95% CI)			**100.0%**	**0.94 [0.86, 1.01]**

Heterogeneity: Chi² = 1.12, df = 3 (P = 0.77); I² = 0%
Test for overall effect: Z = 1.61 (P = 0.11)



A

Study or Subgroup	log[Odds Ratio]	SE	Weight	Odds Ratio IV, Random, 95% CI
de Abajo FJ 2020	0.122	0.077	42.4%	1.13 [0.97, 1.31]
Giorgi Rossi P 2020	0.262	0.079	41.8%	1.30 [1.11, 1.52]
Mehta N 2020	0.61	0.211	15.8%	1.84 [1.22, 2.78]
Total (95% CI)			**100.0%**	**1.29 [1.07, 1.57]**

Heterogeneity: Tau² = 0.02; Chi² = 5.32, df = 2 (P = 0.07); I² = 62%
Test for overall effect: Z = 2.62 (P = 0.009)



B

Study or Subgroup	log[Odds Ratio]	SE	Weight	Odds Ratio IV, Fixed, 95% CI
de Abajo FJ 2020	0.531	0.079	88.9%	1.70 [1.46, 1.99]
Mehta N 2020	0.476	0.224	11.1%	1.61 [1.04, 2.50]
Total (95% CI)			**100.0%**	**1.69 [1.46, 1.96]**

Heterogeneity: Chi² = 0.05, df = 1 (P = 0.82); I² = 0%
Test for overall effect: Z = 7.05 (P < 0.00001)



C

Study or Subgroup	log[Odds Ratio]	SE	Weight	Odds Ratio IV, Fixed, 95% CI
de Abajo FJ 2020	0.329	0.204	10.1%	1.39 [0.93, 2.07]
Giorgi Rossi P 2020	0.262	0.079	67.6%	1.30 [1.11, 1.52]
Mehta N 2020	0.658	0.172	14.3%	1.93 [1.38, 2.71]
Rentsch CT 2020	0.215	0.23	8.0%	1.24 [0.79, 1.95]
Total (95% CI)			**100.0%**	**1.38 [1.21, 1.57]**

Heterogeneity: Chi² = 4.61, df = 3 (P = 0.20); I² = 35%
Test for overall effect: Z = 4.95 (P < 0.00001)



A

Study or Subgroup	log[Odds Ratio]	SE	Weight	Odds Ratio IV, Random, 95% CI
Feng Y 2020	-1.427	1.076	4.3%	0.24 [0.03, 1.98]
Li J 2020	-0.128	0.357	20.1%	0.88 [0.44, 1.77]
Liu Y 2020	-0.562	0.718	8.4%	0.57 [0.14, 2.33]
Mancia G 2020	-0.094	0.143	32.6%	0.91 [0.69, 1.20]
Reynolds HR 2020	0.489	0.101	34.7%	1.63 [1.34, 1.99]
Total (95% CI)			**100.0%**	**1.01 [0.63, 1.60]**

Heterogeneity: Tau² = 0.15; Chi² = 16.21, df = 4 (P = 0.003); I² = 75%
Test for overall effect: Z = 0.02 (P = 0.98)



B

Study or Subgroup	log[Odds Ratio]	SE	Weight	Odds Ratio IV, Random, 95% CI
Feng Y 2020	-1.427	0.372	17.9%	0.24 [0.12, 0.50]
Li J 2020	0.199	0.249	20.8%	1.22 [0.75, 1.99]
Liu Y 2020	-1.079	0.499	14.9%	0.34 [0.13, 0.90]
Mancia G 2020	-0.186	0.142	22.9%	0.83 [0.63, 1.10]
Reynolds HR 2020	0.565	0.091	23.5%	1.76 [1.47, 2.10]
Total (95% CI)			**100.0%**	**0.75 [0.41, 1.39]**

Heterogeneity: Tau² = 0.41; Chi² = 48.85, df = 4 (P < 0.00001); I² = 92%
Test for overall effect: Z = 0.91 (P = 0.36)



C

Study or Subgroup	log[Odds Ratio]	SE	Weight	Odds Ratio IV, Random, 95% CI
Feng Y 2020	-1.561	0.568	7.4%	0.21 [0.07, 0.64]
Huang Z 2020	-0.777	0.651	6.4%	0.46 [0.13, 1.65]
Li J 2020	0.104	0.227	13.2%	1.11 [0.71, 1.73]
Liu Y 2020	-0.916	0.411	9.9%	0.40 [0.18, 0.90]
Mancia G 2020	-0.139	0.102	15.0%	0.87 [0.71, 1.06]
Peng YD 2020	-0.062	0.692	5.9%	0.94 [0.24, 3.65]
Reynolds HR 2020	0.626	0.075	15.3%	1.87 [1.61, 2.17]
Spiegeleer AD 2020	-0.236	0.514	8.2%	0.79 [0.29, 2.16]
Yang G 2020	-0.315	0.392	10.2%	0.73 [0.34, 1.57]
Zeng Z 2020	0.9	0.491	8.5%	2.46 [0.94, 6.44]
Total (95% CI)			**100.0%**	**0.86 [0.57, 1.31]**

Heterogeneity: Tau² = 0.29; Chi² = 65.51, df = 9 (P < 0.00001); I² = 86%
Test for overall effect: Z = 0.68 (P = 0.50)



D

Study or Subgroup	log[Odds Ratio]	SE	Weight	Odds Ratio IV, Fixed, 95% CI
Reynolds HR 2020	-0.105	0.119	98.5%	0.90 [0.71, 1.14]
Yan H 2020	0.207	0.952	1.5%	1.23 [0.19, 7.95]
Total (95% CI)			**100.0%**	**0.90 [0.72, 1.14]**

Heterogeneity: Chi² = 0.11, df = 1 (P = 0.75); I² = 0%
Test for overall effect: Z = 0.85 (P = 0.40)



E

Study or Subgroup	log[Odds Ratio]	SE	Weight	Odds Ratio IV, Fixed, 95% CI
Liu Y 2020	-1.386	0.713	2.3%	0.25 [0.06, 1.01]
Reynolds HR 2020	-0.041	0.115	89.7%	0.96 [0.77, 1.20]
Yan H 2020	-0.261	0.385	8.0%	0.77 [0.36, 1.64]
Total (95% CI)			**100.0%**	**0.91 [0.74, 1.13]**

Heterogeneity: Chi² = 3.68, df = 2 (P = 0.16); I² = 46%
Test for overall effect: Z = 0.83 (P = 0.41)



F

Study or Subgroup	log[Odds Ratio]	SE	Weight	Odds Ratio IV, Fixed, 95% CI
Liu Y 2020	-1.386	0.713	1.2%	0.25 [0.06, 1.01]
Reynolds HR 2020	-0.073	0.082	92.8%	0.93 [0.79, 1.09]
Spiegeleer AD 2020	-0.734	0.76	1.1%	0.48 [0.11, 2.13]
Yan H 2020	-0.198	0.357	4.9%	0.82 [0.41, 1.65]
Total (95% CI)			**100.0%**	**0.90 [0.77, 1.05]**

Heterogeneity: Chi² = 4.13, df = 3 (P = 0.25); I² = 27%
Test for overall effect: Z = 1.30 (P = 0.19)



A

Study or Subgroup	log[Odds Ratio]	SE	Weight	Odds Ratio IV, Random, 95% CI
Li J 2020	-0.094	0.444	43.5%	0.91 [0.38, 2.17]
Mehra MR 2020	-1.109	0.253	56.5%	0.33 [0.20, 0.54]
Total (95% CI)			**100.0%**	**0.51 [0.19, 1.38]**

Heterogeneity: Tau² = 0.38; Chi² = 3.95, df = 1 (P = 0.05); I² = 75%

Test for overall effect: Z = 1.33 (P = 0.18)



medRxiv preprint doi: https://doi.org/10.1101/2020.07.02.20144717; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

B

Study or Subgroup	log[Odds Ratio]	SE	Weight	Odds Ratio IV, Fixed, 95% CI
Li J 2020	-0.261	0.319	23.5%	0.77 [0.41, 1.44]
Mehra MR 2020	0.207	0.177	76.5%	1.23 [0.87, 1.74]
Total (95% CI)			**100.0%**	**1.10 [0.81, 1.49]**

Heterogeneity: Chi² = 1.65, df = 1 (P = 0.20); I² = 39%

Test for overall effect: Z = 0.63 (P = 0.53)



C

Study or Subgroup	log[Odds Ratio]	SE	Weight	Odds Ratio IV, Random, 95% CI
Andrew Ip 2020	-0.416	0.133	19.3%	0.66 [0.51, 0.86]
Bean DM 2020	-0.186	0.131	19.4%	0.83 [0.64, 1.07]
Guo T 2020	0.531	0.506	5.8%	1.70 [0.63, 4.58]
Huang Z 2020	-1.273	1.636	0.7%	0.28 [0.01, 6.91]
Li J 2020	-0.274	0.282	12.1%	0.76 [0.44, 1.32]
Mehra MR 2020	-0.431	0.654	3.9%	0.65 [0.18, 2.34]
Mehta N 2020	0.525	0.401	8.1%	1.69 [0.77, 3.71]
Meng J 2020	1.535	1.66	0.7%	4.64 [0.18, 120.13]
Richardson S 2020	0.231	0.135	19.2%	1.26 [0.97, 1.64]
Zeng Z 2020	-0.431	0.866	2.4%	0.65 [0.12, 3.55]
Zhang P 2020	-0.994	0.392	8.3%	0.37 [0.17, 0.80]
Total (95% CI)			**100.0%**	**0.87 [0.66, 1.15]**

Heterogeneity: Tau² = 0.09; Chi² = 23.27, df = 10 (P = 0.010); I² = 57%

Test for overall effect: Z = 0.99 (P = 0.32)



D

Study or Subgroup	log[Odds Ratio]	SE	Weight	Odds Ratio IV, Random, 95% CI
Giorgi Rossi P 2020	-0.03	0.169	51.3%	0.97 [0.70, 1.35]
Mehra MR 2020	-1.309	0.269	48.7%	0.27 [0.16, 0.46]
Total (95% CI)			**100.0%**	**0.52 [0.15, 1.82]**

Heterogeneity: Tau² = 0.77; Chi² = 16.21, df = 1 (P < 0.0001); I² = 94%

Test for overall effect: Z = 1.02 (P = 0.31)



E

Study or Subgroup	log[Odds Ratio]	SE	Weight	Odds Ratio IV, Random, 95% CI
Bean DM 2020	-0.462	0.148	27.3%	0.63 [0.47, 0.84]
Giorgi Rossi P 2020	-0.03	0.169	26.6%	0.97 [0.70, 1.35]
Mehra MR 2020	-1.309	0.269	22.6%	0.27 [0.16, 0.46]
Yang G 2020	-1.139	0.784	7.9%	0.32 [0.07, 1.49]
Zhang P 2020	-0.994	0.454	15.5%	0.37 [0.15, 0.90]
Total (95% CI)			**100.0%**	**0.51 [0.31, 0.84]**

Heterogeneity: Tau² = 0.22; Chi² = 18.57, df = 4 (P = 0.0010); I² = 78%

Test for overall effect: Z = 2.62 (P = 0.009)